Angimmune LLC   Report issue

For profit Phase 2
Founded: Rockville MD United States (2014)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2014
NCT00611208
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

pembrolizumab (keytruda) (1 trial)

resimmune (4 trials)

vorinostat (zolinza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, T-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanoma (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Sezary Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3